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Abstract
Background: Systematic reviews and meta-analyses that compare 
simultaneous, delayed and liver-first approach for synchronous colo-
rectal liver metastases have found no significant differences. The aim 
of this study was to determine the best treatment strategy on the basis 
of effect sizes and the probabilities of treatment ranking by using a 
network meta-analysis. Moreover, first-time pairwise and network 
meta-analyses were used to estimate the existing evidence, and their 
results were compared to detect any discrepancies between them.
Methods: Systematic review, pairwise meta-analysis and network me-
ta-analysis were performed. The primary and secondary outcomes were 
5-year overall survival and postoperative major morbidity, respectively.
Results: No significant differences in long-term survival and major 
morbidity were found amongst the three approaches. The hazard ratios 
(95% confidence interval) for 5-year overall survival for the simulta-
neous, delayed and liver-first approaches were 0.93 (0.69 - 1.24, P = 
0.613), 0.97 (0.87 - 1.07, P = 0.596) and 0.90 (0.67 - 1.22, P = 0.499), 
respectively. Moreover, the liver-first approach with a surface under 
the cumulative ranking area score of 89% was ranked as the potential-
ly best treatment option based on probabilities of treatment ranking.
Conclusions: On the basis of the relative ranking of treatments, the 
liver-first approach ranked first, followed by the delayed and simulta-
neous approaches. Therefore, a three-arm randomized controlled trial 
that compares the liver-first, simultaneous and delayed approaches 
needs to shed further light as to which is the best treatment option.
Keywords: Synchronous colorectal liver metastases; Simultaneous; 
Delayed; Liver-first; Liver resection; Hepatectomy
Introduction
Compared with patients with metachronous metastases, those 
with synchronous colorectal liver metastases (SCRLM) repre-
sent the cohort with the worst prognosis [1]; however, long-
term survival can be achieved [2].
Three principal treatment strategies are available for these 
patients with potentially resectable SCRLM, namely classic 
or delayed, simultaneous and liver-first approaches [3]. How-
ever, the optimal sequence of colorectal resection has not been 
clearly defined and remains controversial [4]. The current 
evidence based on systematic reviews and conventional meta-
analysis has been inconclusive [4].
Network meta-analysis is an evidence synthesis tool that 
can compare three or more interventions or treatments. It is 
particularly useful when the comparative effectiveness of in-
terventions of numerous studies needs to be compared with 
multiple treatments and mixed treatment comparisons. Anoth-
er advantage of network meta-analysis to the traditional meta-
analysis is that it can be used to estimate not only direct but 
also indirect evidence. Direct evidence can be estimated from 
head-to-head comparisons between interventions performed 
within individual studies. On the other hand, indirect evidence 
is based on comparisons between interventions inferred from 
the network via a common comparator study [5].
The aim of this study was to determine the probability per-
centage of the three possible strategies to treat SCRLM and 
rank these by using the network meta-analysis. Moreover, for 
the first time, the existing evidence was estimated and com-
pared with both pairwise and network meta-analyses.
Materials and Methods
The PRISMA Statement checklist for reporting systematic re-
views and meta-analyses was followed in this study [6].
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Literature search
Using both free texts and MESH terms (synchronous colo-
rectal liver metastases; resectable; liver-first hepatectomy and 
liver resection; simultaneous hepatectomy and liver resection; 
delayed hepatectomy and liver resection), a systematic litera-
ture search was performed in the Medline, Embase, PubMed 
and Google Scholar databases from their inception until March 
2019. Abstracts were selected. References of the retrieved arti-
cles were checked manually for further studies. Any discrepan-
cies between the authors were resolved by consensus discus-
sion among the authors.
Study selection and inclusion and exclusion criteria
Only studies that compared 1) simultaneous and delayed, 2) liver-
first and simultaneous and 3) liver-first and delayed hepatic resec-
tions for SCRLM were included in the review. Time, language, 
and region restrictions were not applied in the systematic review.
Data extraction and outcomes
Two researchers (PG and KK) independently extracted the fol-
lowing summary data for the included studies: name of au-
thors, study design and time period; number of patients includ-
ed for simultaneous, delayed and liver-first hepatic resections; 
age; sex; colonic primaries; patients treated with neoadjuvant 
and adjuvant therapies; major hepatectomies.
The primary and secondary outcomes were long-term 
overall survival and postoperative major morbidity (Clavien-
Dindo III and IV), respectively [7].
Statistical analysis
The methodological quality of all the included studies was as-
sessed using the validated Newcastle-Ottawa scale (NOS) [8]. 
Studies with scores of ≥ 7 were considered of high quality.
First, a pairwise meta-analysis was performed for studies 
that compared two surgical approaches. Subsequently, a net-
work meta-analysis was conducted to compare simultaneous, 
delayed and liver-first approaches. Statistical analysis was con-
ducted using Stata version 15 software (Stata Corp LP, College 
Station, TX, USA). Dichotomous variables were analyzed on 
the basis of odds ratios (ORs) with 95% confidence intervals 
(CIs). Long-term survival was analyzed by combining the haz-
ard ratios (HRs) and 95% CIs from the included studies. These 
were rarely reported and so were estimated using the method 
described by Parmar et al [9], where this was possible. For stud-
ies that reported the numbers at risk, these were combined with 
either the quoted survival rates or values read from enlarged 
plots of the Kaplan-Meier curves to produce the estimates. 
Where numbers at risk were not quoted, constant censoring 
over the follow-up period was assumed in the estimation.
In all the analyses, the point estimate was considered sig-
nificant at P values of < 0.05. Publication bias was examined 
for the primary outcomes by assessing visual asymmetry on a 
funnel plot [10].
Network meta-analysis was performed using hierarchical 
random-effects models [11]. A fixed-effects model was also 
used to estimate if any discrepancy could be demonstrated be-
tween the results of the two models. Quantitative data synthesis 
of the connected network of the studies was conducted with the 
software package WinBUGS version 1.4.3 (MRC Biostatistics 
Unit, Cambridge, UK) [12]. The pooled estimates were ob-
tained using the Markov chain Monte Carlo method. Minimally 
informative priors with vague normal prior distributions were 
used [12]. For each model, 200,000 simulations were generated 
for the two sets of different initial values, and the first 5,000 
simulations were discarded as the burn-in period. The Brooks-
Gelman-Rubin statistics was used for the assessment of con-
vergence [12]. The point estimate was estimated as the median 
of the posterior distribution based on 200,000 simulations; the 
corresponding 95% credible intervals were obtained using the 
2.5th and 97.5th percentiles of the posterior distribution, which 
can be interpreted in a similar way as 95% CIs [13]. The incon-
sistency and heterogeneity of the direct and indirect evidence 
for the three surgical approaches were estimated.
The 95% prediction intervals were calculated with a ran-
dom-effects model and reported to assess further statistical 
heterogeneity. They demonstrated an effect variance among 
studies and predicted a more conservative summary treatment 
effect for a future similar trial [14, 15].
The node splitting method was used to calculate the in-
consistency of the model, which separated evidence into direct 
and indirect; then, the agreement between the two was evalu-
ated and reported with diagnostic information criterion (DIC) 
and effect estimates of direct and indirect evidence [14, 15].
To measure the treatment efficacy, the probability of each 
treatment being the best was calculated. Plots of cumulative 
ranking probabilities (rankograms) were created to demon-
strate how each treatment ranks against each other in terms of 
being the first, second, or third best. The larger the area under 
the cumulative probability ranking curve, the better the treat-
ment than the rest [16].
Definitions
Major hepatectomy was defined as a liver resection of ≥ 3 seg-
ments. Postoperative major morbidity was classified in accord-
ance with the Clavien-Dindo classification [7].
Results
Study selection, characteristics and NOS
Thirty-two retrospective studies were selected from among 
1,165 studies [17-48] (Fig. 1), of which 22 (68.75%) were of 
high quality, with an NOS score of ≥ 7 (Table 1) [19, 21, 22, 
24, 25, 27-29, 33, 34, 36-42, 44-48].
No statistically significant difference was found in the de-
mographic characteristics among the three approaches and in 
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the proportion of colon primaries and rectal tumors between the 
simultaneous and delayed cohorts (P = 0.521). However, the 
number of rectal tumors was significantly higher in the liver-
first cohort (P = 0.001) [35, 40, 41, 47, 48] than in the other 
cohorts. A significantly higher number of patients in the delayed 
and liver-first cohorts than in the simultaneous cohort underwent 
a major hepatic resection (P < 0.001; Table 1). The proportion of 
patients with bilobar distribution of metastases was significantly 
lower in the simultaneous cohort than in the delayed and liver-
first cohorts (P < 0.001) [19-21, 26-29, 31, 37, 39-41, 44-48].
Results from the pairwise meta-analysis of primary and 
secondary outcomes
No significant difference in long-term overall survival was 
found in the three head-to-head comparisons as follows: si-
multaneous versus delayed (HR: 0.97, 95% CI: 0.88 - 1.08, P = 
0.60, I2 = 0%), liver-first versus simultaneous (HR: 0.90, 95% 
CI: 0.55 - 1.47, P = 0.67, I2 = 0%) and liver-first versus delayed 
approaches (HR: 0.88, 95% CI: 0.56 - 1.39, P = 0.59, I2 = 45%; 
Supplementary Fig. 1, www.jocmr.org).
Similarly, no evidence of a significant difference was 
found between the simultaneous and delayed (OR: 1.06, 95% 
CI: 0.9 - 1.25, P = 0.29; I2 = 41%), liver-first and simultaneous 
(OR: 0.58, 95% CI: 0.15 - 2.19; I2 = 0%, P = 0.734) and liver-
first and delayed approaches (OR: 0.56, 95% CI: 0.21 - 1.52; 
I2 = 0%, P = 0.567) with respect to major morbidity (Clavien-
Dindo III and IV; Supplementary Fig. 2, www.jocmr.org).
Results from the network meta-analysis of primary and 
secondary outcomes
In the present study, the Bayesian network meta-analysis in-
cluded 2,235 patients in the simultaneous cohort, 3,824 in the 
Figure 1. Flow diagram of the search strategy and selection of studies.
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Table 1.  Included Studies, Patient Demographics and Characteristics, and Newcastle-Ottawa Scale (NOS) Score [17-48]
Author, year, study design,  
period, country
Number of pa-
tients (S/D/LF)
Gender (M), n 
(%) (S/D/LF) Age (S/D/LF)
Colonic prima-
ries (S/D/LF)
Major liver re-
section (S/D/LF)
NOS 
(max.: 9)
Fukami et al [46], 2016, 
RS, 2006 - 2013, Japan
41/22/0 18 (44)
12 (55)
P = 0.442
65 ± 9
65 ± 7
P = 0.755
25 (61)
10 (46)
P = 0.291
9 (22)
7 (32)
P = 0.091
8
Silberhumer et al [45], 2016, 
RS, 1984 - 2008, USA
320/109/0 176 (53)
68 (62)
P = 0.10
59 ± 13
59 ± 12
P = 0.601
177 (55)
56 (51)
P = 0.383
107 (33)
79 (73)
P = 0.01
8
Tanaka et al [48], 2015, Japan 0/30/10 8 (27)
5 (50)
P = 0.246
61 (37 - 80)
63 (39 - 74)
P = 0.696
22 (73)
8 (80)
P = 0.001
18 (61)
7 (70)
P = 0.527
8
She et al [44], 2014, RS, 1990 
- 2008, Hong Kong, China
28/88/0 22 (79)
59 (67)
P = 0.25
65 (29 - 75)
59 (24 - 81)
P = 0.06
15 (54)
69 (78)
P = 0.01
12 (43)
54 (61)
P = 0.09
8
Andres et al [47], 2012, 
Multicenter International
0/729/58 440 (60)
41 (71)
P = 0.109
60 ± 11
59 ± 11
P = 0.710
558 (77)
25 (43)
P < 0.001
NR 8
Patrono et al [43], 2014, 
RS, 1997 - 2012, Italy
46/60/0 24 (52)
37 (61)
P = 0.33
64 ± 11
61 ± 9
P = 0.201
38 (83)
47 (78)
P = 0.633
22 (48)
42 (70)
P = 0.03
6
Abbott et al [42], 2012, 
RS, 1993 -2010, USA
60/84/0 40 (61)
49 (58)
P = ns
57 (45 - 64)
54 (46 - 68)
P = 0.163
26 (43)
31 (37)
P = 0.441
20 (33)
63 (75)
P = 0.001
7
Mayo et al [41], 2012, RS, 1982 
- 2011, Multicenter International
329/647/28 185 (56)
396 (68)
17 (60)
P = ns
60 ± 30
61 ± 18
58 ± 12
P > 0.05
238 (72)
475 (74)
13 (46)
P = 0.007
78 (24)
250 (39)
10 (36)
P < 0.001
8
Brouquet et al [40], 2010, 
RS, 1992 - 2009, USA
43/72/27 23 (53)
44 (61)
10 (37)
P = ns
58 (31 - 77)
56 (25 - 81)
48 (25 - 78)
P = 0.02
25 (58)
37 (51)
19 (70)
P = 0.02
15 (35)
48 (66)
24 (89)
8
de Haas et al [39], 2010, 
RS, 1990 - 2006, France
55/173/0 28 (51)
107 (62)
P = 0.914
56
58
P = 0.323
47 (85)
110 (64)
P = 0.267
NR 8
Luo et al [38], 2010, RS, 
1994 - 2008, China
129/276/0 76 (59)
156 (57)
P = 0.650
58
60
P = 0.720
60 (47)
138 (50)
P = 0.470
44 (34)
133 (48)
P = 0.054
7
Kaibori et al [37], 2010, 
RS, 1993 - 2007, Japan
32/42/0 27 (53)
27 (64)
P = 0.332
65
62
P = 0.233
17 (53)
9 (21)
P = 0.084
10 (32)
9 (38)
P = 0.90
9
Moug et al [36], 2010, RS, UK 32/32/0 18 (56)
21 (66)
P = ns
69
67
P ≥ 0.05
17 (53)
17 (53)
P = ns
7 (22)
7 (22)
P = ns
8
Van der Pool et al [35], 2010, RS, 
2000 - 2007, The Netherlands
8/29/20 NR NR All rectal NR 6
Slupski et al [34], 2009, 
RS, 1997 - 2006, Poland
28/61/0 18 (64)
34 (56)
P = 0.48
59
60
P = 0.710
NR 8 (28)
29 (48)
P = 0.10
7
Martin et al [33], 2009, 
RS, 1997 - 2008, USA
70/160/0 38 (54)
83 (52)
P = 0.7
58
61
P = 0.06
49 (70)
123 (77)
P = ns
33 (47)
64 (40)
P = ns
7
Petri et al [32], 2008, RS, 
1999 - 2008, Hungary
14/29/0 8 (57)
17 (59)
P = nr
60
64
P = nr
NR 0%
6 (29)
P = 0.155
6
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press Inc™   |   www.jocmr.org576
Hepatic Resections for SCRLM J Clin Med Res. 2019;11(8):572-582
Author, year, study design,  
period, country
Number of pa-
tients (S/D/LF)
Gender (M), n 
(%) (S/D/LF) Age (S/D/LF)
Colonic prima-
ries (S/D/LF)
Major liver re-
section (S/D/LF)
NOS 
(max.: 9)
Yoshidome et al [31], 2008, 
RS, 1985 - 2006, Japan
116/21/0 71 (58)
12 (52)
P = 0.914
NR 67 (58)
11 (52)
P = 0.820
NR 6
Reddy et al [30], 2007, 
RS, 1985 - 2005, USA
135/474/0 84 (62)
275 (58)
P = 0.47
57
58
P = 0.641
81 (60)
365 (77)
P = 0.001
36 (27)
291 (61)
P = 0.001
6
Thelen et al [29], 2007, RS, 
1988 - 2005, Germany
40/179/0 24 (60)
96 (54)
P = 0.465
60
60
P = 0.731
34 (85)
107 (60)
P = 0.04
15 (38)
141 (79)
P = 0.001
7
Yan et al [28], 2007, 
OCS, Australia
73/30/0 48 (47)
37 (45)
P = 0.671
60
59
P = 0.821
58 (79)
18 (60)
P = 0.05
54 (74)
22 (73)
P = ns
8
Capussotti et al [27], 2007, 
RS, 1984 - 2004, Italy
70/57/0 40 (54)
35 (59)
P = 0.710
65
60
P = 0.10
43 (61)
37 (65)
P = 0.713
24 (34)
32 (56)
P = 0.01
8
Turini et al [26], 2007, RS, 
1996 - 2004, France
57/62/0 NR 60
59
P = 0.08
33 (58)
42 (68)
P = 0.07
7 (25)
23 (29)
P = ns
6
Vassiliou et al [25], 2007, 
RS, 1996 - 2004, Greece
25/78/0 15 (59)
47 (61)
P = ns
63
61
P = ns
22 (88)
70 (89)
P = ns
NR 8
Taniai et al [24], 2006, 
RS, 1990 - 2002, Japan
67/41/0 35 (52)
25 (61)
P = 0.375
63
63
P = 0.628
25 (37)
14 (34)
P = 0.733
NR 6
Minagawa et al [23], 2006, 
RS, 1980 - 2002, Japan
142/18/0 NR NR 70 (49)
14 (78)
P = 0.02
16 (11)
7 (38)
P = 0.005
5
Chua et al [22], 2004, RS, 
1996 - 1999, USA
64/32/0 39 (61)
18 (56)
P = 0.7
63
61
P = 0.34
29 (46)
17 (54)
P = 0.520
10 (16)
13 (40)
P = 0.01
9
Tanaka et al [21], 2004, Japan 39/37/0 20 (51)
25 (68)
P = ns
NR 25 (65)
20 (53)
5 (13)
22 (59)
P < 0.01
7
Weber et al [20], 2000, RS, 
1987 - 2000, France
35/62/0 18 (51)
31 (50)
P = 0.89
58
60
P = 0.54
25 (71)
38 (61)
P = 0.431
11 (31)
35 (56)
P = 0.01
5
Jaeck et al [19], 1999, RS, France 28/31/0 NR 56
60
P = 0.70
22 (78)
19 (61)
P = 0.170
11 (32)
17 (52)
P = 0.11
7
Vogt et al [18], 1991, RS, 
1977 - 1987, Germany
19/17/0 NR NR NR 6 (32)
9 (53)
P = 0.521
5
Scheele et al [17], 1991, RS, 
1960 - 1988, Germany
90/42/0 NR NR NR NR 6
Pooled total, 6,202 P = ns P = ns 61%
66%
59%
P = 1.00
565 (30)
1,415 (53)
41 (29)
P < 0.001
Higher 
quality 22
S: simultaneous; D: delayed; LF: liver-first; ns: non-significant; NR: not reported; NOS: Newcastle-Ottawa scale; RS: retrospective study.
Table 1.  Included Studies, Patient Demographics and Characteristics, and Newcastle-Ottawa Scale (NOS) Score [17-48] - (contin-
ued)
Articles © The authors   |   Journal compilation © J Clin Med Res and Elmer Press Inc™   |   www.jocmr.org 577
Gavriilidis et al J Clin Med Res. 2019;11(8):572-582
delayed cohort and 143 in the liver-first cohort. The network 
of evidence of the three surgical approaches was demonstrat-
ed with a closed loop (triangle; Supplementary Fig. 3, www.
jocmr.org).
Patient long-term survival was similar between the simulta-
neous, delayed, and liver-first approaches of the network of evi-
dence (HR: 0.93, 95% CI: 0.69 - 1.24, P = 0.613; HR: 0.97, 95% 
CI: 0.87 - 1.07, P = 0.596; and HR: 0.90, 95% CI: 0.67 - 1.22, 
P = 0.499, respectively). Moreover, the evaluation of inconsist-
ency using loop-specific heterogeneity was estimated to be non-
significant (relative OR (ROR): 1.185, 95% CI: 1.00 - 10.54, P = 
0.974; τ2 = 0.288; Supplementary Fig. 4, www.jocmr.org).
Similar to the pairwise meta-analysis, the network meta-
analysis showed no differences in postoperative major morbid-
ity amongst the three surgical approaches. The OR and CIs 
for the comparison between the simultaneous and delayed 
approaches were 0.94 and 0.67 - 1.32; between the liver-first 
and simultaneous approaches, 0.52 and 0.20 - 1.39; and be-
tween the liver-first and delayed approaches were 0.57 and 
0.21 - 1.45, respectively. Their predictive intervals (95% PrI) 
for similar future trials were also non-significant (0.25 - 3.53, 
0.10 - 2.68 and 0.11 - 2.82, respectively; Fig. 2).
Ranking probabilities for competing treatments
Rankograms of the cumulative ranking probabilities of the best 
approach based on overall survival and major morbidity were 
created. The best surgical approach was the one with the larg-
est area under the cumulative probability ranking curve. All 
approaches were compared with both estimated and predictive 
probabilities. Comparing the treatment relative ranking of es-
timated probabilities, the liver-first group was the best, with 
a surface under cumulative ranking area (SUCRA) of 90.3%; 
the delayed group was second, with an SUCRA of 36.6%; and 
the simultaneous group was third, with an SUCRA of 23.1% 
(Fig. 3).
The ranking of the three surgical approaches according to 
the predictive probabilities was the same. However, the SU-
CRA decreased for the liver-first group from 90.3% to 78.5%; 
on the contrary, the SUCRA of the simultaneous group in-
creased from 23.1% to 33.1% and that for the delayed group 
slightly increased from 36.6% to 38.5% (Fig. 3).
Sensitivity, heterogeneity, inconsistency analysis and pub-
lication bias
No significant discrepancies were found when comparing the 
95% CI with the 95% PrI of all pairwise comparisons in the 
present Bayesian network meta-analysis (Fig. 3). The evalu-
ation of inconsistency using loop-specific heterogeneity was 
estimated to be non-significant (ROR: 1.185, 95% CI: 1.00 
- 10.54; Supplementary Fig. 4, www.jocmr.org). In addition, 
Figure 2. Predictive interval plot of the three surgical approaches. The blue line represents the line of no effect (OR: 1). The black 
and red lines denote confidence and predictive intervals, respectively. OR: odds ratio.
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the random-effects standard deviation of 0.0493 and time-
series standard error of 0.0008 proved the consistency of the 
model. First, the arbitrary starting values did not have an un-
due influence on the sampling process. Second, the quantities 
of interest were estimated with sufficient accuracy. The time-
series plot demonstrated a converged chain that contained suf-
ficient information for accurate inferences; the potential scale 
reduction factor (PSRF) reached stable values of < 1.01, and 
the series plot of the estimation accuracy showed smooth den-
sity and tapering off of the extreme values in the tails. Fur-
thermore, no inconsistency of the model was found using the 
node-splitting method. An agreement between the direct and 
indirect evidence amongst the three node-split models was 
found (Fig. 4).
A comparison-adjusted funnel plot of bias showed some 
indication of publication bias, with asymmetry amongst the 
smaller studies. However, because of the low weighting of 
these studies, the effect of this potential bias on the results was 
negligible (Fig. 5).
Discussion
The network meta-analysis in this study demonstrates that 
no currently used strategy to resect SCRLM has superiority 
over another in terms of survival or perioperative complica-
tions. The Bayesian computation with fixed-effects model did 
not show any discrepancies with the random-effects model. 
In a recent meta-analysis of a pairwise comparison of simul-
taneous and delayed approaches, we reported an absence of 
evidence of significant differences in long-term survival and 
safety [49].
In the present study, for the first time, pairwise and net-
work meta-analyses were simultaneously conducted for the 
three surgical approaches. The advantages, disadvantages, 
and limitations of the three treatment strategies remain con-
Figure 3. Rankograms of probability of each treatment being first, second, or third. The liver-first approach has an 86% probabil-
ity of being the best, followed by the delayed and simultaneous approaches, with 8% and 5% probability, respectively. SUCRA: 
surface under the cumulative ranking area.
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troversial [4]. The liver-first approach was ranked as the best 
treatment with respect to its relative efficacy on the basis of 
5-year overall survival outcomes and postoperative compli-
cation rate. It is interesting that the treatment relative rank-
ing of the predictive probabilities demonstrated that as the 
liver-first approach will be applied more often in the future, 
Figure 4. Node-split model (1 - 2): simultaneous vs. delayed; node-split model (1 - 3): simultaneous vs. liver-first; node-split 
model (2 - 3): delayed vs. liver-first. An agreement between direct and indirect evidence exists. The DIC demonstrates goodness 
of fit of the model. DIC: deviance information criterion.
Figure 5. Comparison-adjusted funnel plot of publication bias.
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its SUCRA will decrease from 89% to 77%, but it would still 
represent the better treatment option than the other two. The 
SUCRA score expresses the percentage of effectiveness or 
safety of each treatment as compared with that of an “ideal” 
treatment that always rank first without uncertainty [16]. The 
same method showed that the simultaneous and delayed ap-
proaches can be extensively and slightly improved, respec-
tively. In general, the ranking will remain the same in future 
trials. Network meta-analysis offers clinicians this new tool. 
Clinical decisions about the choice of the best treatment strat-
egy can be suggested on the basis of the probabilities of treat-
ment ranking.
To the authors’ best knowledge, this is the biggest network 
meta-analysis, which included 32 studies. The previous study 
included 18 studies and had a principal methodological weak-
ness of estimating survival with OR [49]. Survival by default 
is estimated with HR, and if the authors of the included studies 
rarely report them, then they can be estimated with the method 
described by Parmar [9, 50, 51].
Conclusion
The evidence from this study supports the application of any of 
the three surgical strategies, provided they are applied to care-
fully selected patients. The principal limitation of this study is 
that it included only retrospective studies and a small number 
of studies that compared the liver-first approach with other ap-
proaches. Moreover, readers should also take into account that 
creation of rankograms based on probabilistic statistics should 
be interpreted accordingly. Therefore, their results should be 
compared with those of the conventional frequentist meta-
analysis and adequate conclusions should be made.
In addition, a topic that needs special attention and fur-
ther investigation is the surveillance strategy of SCRLM. More 
than 20% of patients with intensive surveillance were eligi-
ble for redo hepatic resections as compared with patients with 
less-intensive surveillance. Moreover, they demonstrated more 
survival benefits [52]. Therefore, future randomized controlled 
trials with predefined surgical outcome parameters, short- and 
long-term mortality rates, follow-up of 5 - 10 years, and more-
intensive surveillance may help further elucidate the efficacy 
of the three surgical procedures.
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